Tc‐99m mebrofenin hepatobiliary scintigraphy to assess future liver remnant function before major liver surgery
Journal of Surgical Oncology · 2023-12 · 128 (8) · 1312-1319
DOI: 10.1002/jso.27426 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 28.08.2023. Verfasst von Héloïse Smet und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Visceral Surgery, Lausanne University Hospital CHUV, Lausanne and University of Lausanne (UNIL), Lausanne, Switzerland. Hauptthemen laut MEDLINE: Liver Failure, Liver Neoplasms, Embolization, Therapeutic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Objectives Assessment of liver function is paramount before hepatectomy. This study aimed to assess future liver remnant function (FLR‐F) using hepatobiliary scintigraphy (HBS) and to compare it to FLR volume (FLR‐V) in the prediction of posthepatectomy liver failure (PHLF). The impact of volume and function gains were also assessed in patients undergoing portal vein embolization (PVE) or liver venous deprivation (LVD).
Methods
All consecutive patients undergoing major hepatectomy between 02/2018 and 09/2021 with preoperative HBS were included. FLR‐V was expressed as percentage of total liver volume and analyzed using preoperative computed tomography. FLR‐V and FLR‐F gains after embolization were expressed in percentage. Receiver operating characteristic analysis was performed to compare both methods in predicting PHLF.
Results
Thirty‐six patients were included. PVE and LVD were performed in 4 (11%) and 28 patients (78%), respectively. Overall, PHLF occurred in eight patients (22%). FLR‐F gain after embolization showed significant ability to predict PHLF (area under the curve [AUC] = 0.789), with cut‐off value of 150% showing a sensitivity of 1.00, a specificity of 0.42, and a negative predictive value of 1.00.
Conclusion
Preoperative HBS shows a high sensitivity to predict PHLF when HBS is performed twice to measure the function gain after venous embolization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Visceral Surgery, Lausanne University Hospital CHUV, Lausanne and University of Lausanne (UNIL), Lausanne, Switzerland.
- Department of Diagnostic and Interventional Radiology, Lausanne University Hospital CHUV, Lausanne and University of Lausanne (UNIL), Lausanne, Switzerland.
- Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital CHUV, Lausanne and University of Lausanne (UNIL), Lausanne, Switzerland.
Zitieren
APA
Smet, H., Martin, D., Uldry, E., Duran, R., Girardet, R., Schaefer, N., Prior, J. O., Denys, A., Halkic, N., Demartines, N., & Melloul, E. (2023). Tc‐99m mebrofenin hepatobiliary scintigraphy to assess future liver remnant function before major liver surgery. Journal of Surgical Oncology, 128(8), 1312-1319. https://doi.org/10.1002/jso.27426
Vancouver
Smet H, Martin D, Uldry E, Duran R, Girardet R, Schaefer N, et al. Tc‐99m mebrofenin hepatobiliary scintigraphy to assess future liver remnant function before major liver surgery. Journal of Surgical Oncology. 2023;128(8):1312-1319. doi:10.1002/jso.27426
BibTeX
@article{Smet2023,
author = {Smet, Héloïse and Martin, David and Uldry, Emilie and Duran, Rafaël and Girardet, Raphael and Schaefer, Niklaus and Prior, John O and Denys, Alban and Halkic, Nermin and Demartines, Nicolas and Melloul, Emmanuel},
title = {Tc‐99m mebrofenin hepatobiliary scintigraphy to assess future liver remnant function before major liver surgery},
journal = {Journal of Surgical Oncology},
year = {2023},
volume = {128},
number = {8},
pages = {1312--1319},
doi = {10.1002/jso.27426}
}
EUVIMED